{"id":"W2069236338","doi":"10.1111/bjd.13745","title":"A phase 2a randomized, double-blind, placebo-controlled, sequential dose-escalation study to evaluate the efficacy and safety of ASP015K, a novel Janus kinase inhibitor, in patients with moderate-to-severe psoriasis","year":2015,"lang":"en","type":"article","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":116,"is_retracted":false,"has_abstract":true,"ca_institutions":"Probity Medical Research","funders":"U.S. Food and Drug Administration; Astellas Pharma","keywords":"Medicine; Psoriasis; Placebo; Psoriasis Area and Severity Index; Dosing; Adverse effect; Body surface area; Internal medicine; Clinical endpoint; Dermatology Life Quality Index; Clinical trial; Gastroenterology; Randomized controlled trial; Janus kinase; Urology; Cytokine; Dermatology; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002919568,0.002015696,0.003291308,0.0005632443,0.0005809917,0.000961971,0.001171224,0.001695494,0.006293921],"category_scores_gemma":[0.002386412,0.0009540524,0.001419172,0.0004630873,0.00146254,0.001252987,0.0005015495,0.003066348,0.00106858],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007156313,"about_ca_system_score_gemma":0.001553903,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005520046,"about_ca_topic_score_gemma":0.001264271,"domain_scores_codex":[0.9989285,0.0005577556,0.0000703593,0.0002098894,0.0001179952,0.0001154268],"domain_scores_gemma":[0.9985164,0.0003578696,0.0003496733,0.0001593553,0.0001283997,0.0004882463],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9445108,0.03130272,0.000804318,0.000321043,0.00051702,0.00003390398,0.00006630649,0.0003467131,0.007394357,0.00007846257,0.0006796874,0.01394478],"study_design_scores_gemma":[0.908653,0.08916122,0.001265215,0.000007287425,0.0001102933,0.00002022388,0.000007807595,0.0001877463,0.0002856351,0.0000534414,0.0002405892,0.000007559173],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9843933,0.001533112,0.001197987,0.0004979037,0.0003776707,0.009182281,0.001020278,0.0001447148,0.001652904],"genre_scores_gemma":[0.9768296,0.001305356,0.004071506,0.001518955,0.0005272125,0.01128622,0.001643997,0.00003533714,0.002781947],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006293921,"threshold_uncertainty_score":0.02105528,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02685597107351539,"score_gpt":0.2808812005526604,"score_spread":0.254025229479145,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}